Delamanid-containing regimens and multidrug-resistant tuberculosis: A systematic review and meta-analysis
Mohammad Javad Nasiri, Moein Zangiabadian, Erfan Arabpour, S. Amini, Farima Khalili, Rosella Centis, Lia D’Ambrosio, Justin T. Denholm, H. Simon Schaaf, Martin van den Boom, Xhevat Kurhasani, Margareth Pretti Dalcolmo, Seif Al-Abri, Jeremiah Chakaya, Jan‐Willem C. Alffenaar, Onno W. Akkerman, Denise Rossato Silva, Marcela Muñóz-Torrico, Barbara Seaworth, Emanuele Pontali, Laura Saderi, Simon Tiberi, Alimuddin Zumla, Giovanni Battista Migliori, Giovanni Sotgiu
Abstract
INTRODUCTION: Multidrug-resistant tuberculosis (MDR-TB) is a life-threatening condition needing long poly-chemotherapy regimens. As no systematic reviews/meta-analysis is available to comprehensively evaluate the role of delamanid (DLM), we evaluated its effectiveness and safety. METHODS: We reviewed the relevant scientific literature published up to January 20, 2022. The pooled success treatment rate with 95% confidence intervals (CI) was assessed using a random-effect model. We assessed studies for quality and bias, and considered P<0.05 to be statistically significant. RESULTS: : 95.1%) with no evidence of publication bias (Begg's test; P >0.05). CONCLUSIONS: In MDR-TB patients receiving DLM, culture conversion and treatment success rates were high despite extensive resistance with limited adverse events.